Key Documents

View All Documentation

L8533

Lansoprazole

Name: Lansoprazole
Brand: SIGMA

≥98% (TLC), Gastric proton pump inhibitor, powder

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₁₆H₁₄F₃N₃O₂S

CAS Number:

103577-45-3

Molecular Weight:

369.36

UNSPSC Code:

12352200

PubChem Substance ID:

24278520

NACRES:

NA.77

MDL number:

MFCD00866873

Assay:

≥98% (TLC)

Form:

powder

Quality level:

100

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

Product Name

Lansoprazole, ≥98% (TLC), powder

Quality Level

100

assay

≥98% (TLC)

form

powder

color

off-white

originator

Novartis

storage temp.

2-8°C

SMILES string

Cc1c(CS(=O)c2nc3ccccc3[nH]2)nccc1OCC(F)(F)F

InChI

1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)

InChI key

MJIHNNLFOKEZEW-UHFFFAOYSA-N

Gene Information

human ... ATP4A(495), ATP4B(496)

Description

Biochem/physiol Actions

Gastric proton pump inhibitor.

Features and Benefits

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Still not finding the right product?

Explore all of our products under Lansoprazole

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.

L B Barradell et al.

Drugs, 44(2), 225-250 (1992-08-01)

Lansoprazole is an effective acid pump inhibitor acting at the final enzymatic step of the acid secretory pathway of the parietal cell, decreasing gastric acid secretion regardless of the primary stimulus. Results of short term (less than 8 weeks) clinical

Lansoprazole promotes cisplatin-induced acute kidney injury via enhancing tubular necroptosis.

Lin Ye et al.

Journal of cellular and molecular medicine, 25(5), 2703-2713 (2021-02-20)

Acute kidney injury (AKI) is the main obstacle that limits the use of cisplatin in cancer treatment. Proton pump inhibitors (PPIs), the most commonly used class of medications for gastrointestinal complications in cancer patients, have been reported to cause adverse

Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes.

T B Bödvarsdóttir et al.

Diabetologia, 53(10), 2220-2223 (2010-06-30)

Gastrin has been implicated in islet growth/neogenesis, and proton pump inhibitors (PPIs) have been shown to increase endogenous gastrin levels in animals and humans. Therefore, we investigated the effect of PPIs in a model of type 2 diabetes, Psammomys obesus.

View All Related Papers

Global Trade Item Number

SKU	GTIN
L8533-1G	04061833966075
L8533-250MG	04061833966082